The new drug delivery system set to revolutionise the mode of drug administration
Why Oral Thin Films
Conventional oral solid dosage forms like tablets and capsules have
to be swallowed and that too preferably with water or any other
Swallowing may be a hindrance in drug administration for certain
category of patients like children, elderly, mentally challenged,
nauseated, mobile and bed ridden patients
Oral Thin Film provides an alternate, non obstructive dosage form
possessing the advantages of a tablet or capsule but with
convenience of administration that leads to treatment adherence
This unique delivery platform provide possibilities for repurposing
and reformulating generic products to create new or extend
existing brands with a unique new dosage form possessing a high
technology barrier for competition!
Zim is a pioneer and leader in the Oral Thin Film delivery technology. In 2009
Zim conceptualized this patented Thinoral® technology for manufacturing of
instantly wettable, rapidly dissolving, non sticky, non tacky, and non curving
Over the years Zim’s OTF R&D team has further improved on the technology
platform to be therapy agnostic and suitable for delivering by oral, sublingual
and buccal routes.
The technology platform has strong protection through the filing of 30
product process patents, few of which are already granted in various
territories like, US, India, Malaysia, Ukraine, Eurasia etc.
Several pharmaceutical and nutraceutical products based on this OTF
technology have been developed, registered and commercialized
Various innovative products are under co development in association with
MNCs and leading regional players for registration and commercialization in
regulated markets (including Europe and USA)
Our OTF manufacturing facility is EU GMP and WHO GMP approved along
with accreditations from many other regulatory authorities.
Our Growth Plans
Our goal is to develop innovative products addressing unmet
medical needs based on sound research. Our product pipeline
would be a combination of in-house selection or under co-development contracts with our partners
We are working to develop and commercialize products on other
unique technologies like SpinoralTM and PrintoralTM technologies
which can be used for manufacturing of heat and moisture
sensitive products including peptides in the thin film dosage form
We aspire to be the most preferred technology partner for
renowned pharmaceutical marketing companies for the thin film
dosage form in all the regions of the world.
We also wish to leverage on the OTF technology for developing
nutraceutical, vitamins and other Over the Counter (OTC)
pharmaceutical and nutraceutical products for launch in the
developed and advanced markets.
Our Current Focus
Out-licensing the ready product dossiers to established players in
the pharmerging and developed markets.
Completing process validation and bioequivalence studies of our
pipeline products meant for delivery by oral and sublingual route
Filing product applications for registration of our differentiated
products across markets - pharmaceutical and nutraceutical
Entering into marketing, distribution and brand tie ups and
partnerships which may include joint ventures for development,
marketing and distribution of our various products
Developing further our innovative product pipeline, including
non-invasive delivery system for injectable peptide products.
How We Can Work Together
We are keen to partner, for the development and
commercialization of generic pharmaceutical, nutraceutical
and other OTC products on our patented Thinoral ®
We provide comprehensive, integrated R&D and
manufacturing support from the stage of conceptualization
of the product through various studies, dossier readiness,
registrations and launch of the product on mutually
acceptable terms. We possess know-how for enabling
several versatile solutions for improving taste, release,
efficacy, stability, and safety of existing conventional
products and welcome challenging assignments.
For list of our OTF products, please refer Products Section.